In vivo accumulation of the same anti-melanoma T cell clone in two different metastatic sites.
暂无分享,去创建一个
P. J. van den Elsen | L. Boyle | J. Kurnick | D. Andrews | F. Pandolfi | M. Hishii | J. Wong | P. J. V. D. Elsen | J. T. Kurnick | Franco Pandolfi | M. Hishii | David W. Andrews | Johnson T. Wong
[1] I. Stamenkovic,et al. Expression of cell adhesion molecules in human melanoma cell lines and their role in cytotoxicity mediated by tumor‐infiltrating lymphocytes , 2010, Cancer.
[2] K. Masuko,et al. Stable clonal expansion of T cells induced by bone marrow transplantation. , 1996, Blood.
[3] F. Marincola,et al. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.
[4] C. Farina,et al. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[5] K. Sakaguchi,et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. , 1995, Journal of immunology.
[6] T. Eberlein,et al. Immunoregulatory effects of CD4+ T helper subsets in human melanoma. , 1995, Surgery.
[7] S. Rosenberg,et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995 Mar 1;181(3):1261] , 1995, The Journal of experimental medicine.
[8] J. Becker,et al. Maintenance of clonal anergy by endogenously produced IL-10. , 1994, International immunology.
[9] P. Kourilsky,et al. Oligoclonality of tumor-infiltrating lymphocytes from human melanomas. , 1994, Journal of immunology.
[10] D. Moller,et al. Comparative sensitivity of alternative single-strand conformation polymorphism (SSCP) methods. , 1994, BioTechniques.
[11] S. Rosenberg,et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[12] G. Carcelain,et al. Direct evidence to support the immunosurveillance concept in a human regressive melanoma. , 1994, The Journal of clinical investigation.
[13] J. P. Hanson,et al. Molecular cytogenetic mapping of the human melanoma antigen (MAGE) gene family to chromosome region Xq27-qter: implications for MAGE immunotherapy. , 1994, Cancer research.
[14] S. Rosenberg,et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[15] C. Figdor,et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[16] B. Seliger,et al. Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes , 1994, European journal of immunology.
[17] P. Kourilsky,et al. Evidence for T-cell clonal expansion in a patient with squamous cell carcinoma of the head and neck. , 1994, Cancer research.
[18] A. Oliva,et al. T cell receptor gene rearrangements and cytotoxic activities of clones isolated from tumour‐infiltrating lymphocytes (TIL) from melanoma patients , 1994, Clinical and experimental immunology.
[19] T. Eberlein,et al. T cell receptor Vβ2 and Vβ6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer , 1993 .
[20] M. Herlyn,et al. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2- restricted and melanocyte-lineage-specific CTL clone , 1993, The Journal of experimental medicine.
[21] G. Carcelain,et al. Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. , 1993, Cancer research.
[22] F. Breedveld,et al. T-cell receptor V-gene usage in synovial fluid lymphocytes of patients with chronic arthritis. , 1993, Human immunology.
[23] P. Linsley,et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 , 1992, Cell.
[24] S. Roman-Roman,et al. Analysis of T-Cell Receptor α/β Variability in Lymphocytes Infiltrating a Melanoma Metastasis , 1992 .
[25] K. Hayashi. PCR-SSCP: a method for detection of mutations. , 1992, Genetic analysis, techniques and applications.
[26] R. Kradin,et al. Dominant rearrangements among human tumor‐infiltrating lymphocytes. Analysis of T‐cells derived from 32 patients with melanoma, lung, and renal cell carcinoma , 1992, Cancer.
[27] J. Fallon,et al. Cytotoxic activity of graft-infiltrating lymphocytes correlates with cellular rejection in cardiac transplant patients. , 1991, Human immunology.
[28] Freedman Rs,et al. Selective usage of TCR V beta in tumor-specific CTL lines isolated from ovarian tumor-associated lymphocytes. , 1991 .
[29] K. Isselbacher,et al. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition. , 1991, Cancer research.
[30] S. Rosenberg,et al. Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation. , 1991, Journal of immunology.
[31] G. Robbins,et al. Clonal expansion of T cells following in vitro stimulation with autologous melanoma cells and interleukin-2 studied by molecular analysis of a T cell receptor. , 1991, Immunology letters.
[32] A. Anichini,et al. Heterogeneity for integrin expression and cytokine‐mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins , 1991, International journal of cancer.
[33] L. Steinman,et al. Predominant expression of T cell receptor V alpha 7 in tumor-infiltrating lymphocytes of uveal melanoma. , 1990, Science.
[34] J. L. Casanova,et al. Optimal conditions for directly sequencing double-stranded PCR products with sequenase , 1990, Nucleic Acids Res..
[35] S. Rosenberg,et al. Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. , 1990, Journal of immunology.
[36] F. Heuźe,et al. Selective expansion of a specific anti‐tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor‐infiltrating lymphocytes from a melanoma patient: Cytotoxic activity and T cell receptor gene rearrangements , 1990, European journal of immunology.
[37] R. Offringa,et al. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes , 1989, Cell.
[38] R. Kradin,et al. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies. , 1989, Journal of immunology.
[39] N. Chakraborty,et al. Clonal analysis of cytotoxic and regulatory T cell responses against human melanoma , 1989, The Journal of experimental medicine.
[40] T. Boon,et al. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[41] S. Dubinett,et al. TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER , 1989, The Lancet.
[42] F. Preffer,et al. Adoptive immunotherapy with IL-2 results in the loss of delayed-type hypersensitivity responses and the development of immediate hypersensitivity to recall antigens. , 1989, Clinical immunology and immunopathology.
[43] C. Balch,et al. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor , 1988, The Journal of experimental medicine.
[44] E. Jaffe,et al. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. , 1987, The American journal of pathology.
[45] S. Miescher,et al. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. , 1987, Journal of immunology.
[46] R. Blumberg,et al. Functional characterization of T lymphocytes propagated from human lung carcinomas. , 1986, Clinical immunology and immunopathology.
[47] M. Bevan,et al. A reexamination of the role of LYT-2-positive T cells in murine skin graft rejection , 1984, The Journal of experimental medicine.
[48] P. Altevogt,et al. Helper and suppressor-inducer activity of human T cells and their cloned progeny maintained in long-term culture. , 1981, Journal of immunology.
[49] H. Wigzell,et al. Long term growth in vitro of human T cell blasts with maintenance of specificity and function. , 1979, Journal of immunology.
[50] F. Sanger,et al. DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[51] P. Bruggen,et al. Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.
[52] K. Neldner,et al. Letter: Zinc,acrodermatitis enteropathica, and congenital malformations. , 1975, Lancet.